
PRIMA
NCT02655016
JCP012
A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Status:
Closed to Accrual

III
Phase

2nd+
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
HDR, BRCA1/2
Investigational
Product
Niraparib
PARP inhibitor (p.o.)
Treatment Arms
o Experimental: Niraparib
o Placebo Comparator: Placebo